Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
QED Therapeutics, a BridgeBio company
Age
3–18
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
1. Pediatric participants with HCH who have completed ACCEL 2/3
2. Negative pregnancy test in girls ≥10 years of age or girls of any age who have experienced menarche
You may not be if
1. Participant has concurrent medical condition that, in the view of the PI and/or sponsor, would interfere with study participation or safety evaluations
2. Participants who developed a medical condition that requires the initiation of treatment with a prohibited medication
3. Participants who prematurely discontinued ACCEL 2/3
4. Participants who have reached final height or near final height
5. Current participation in an ongoing clinical study with a sponsor other than QED
Clareo Health | Open-Label, Long-Term, Extension Study of Infigratinib in Children With Hypochondroplasia
